Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib and KN046 in Advanced Gastrointestinal Tumors
NCT04612712Phase 2Terminated
- Sponsor
- Zelgen
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib and erfonrilimab in gastrointestinal tumor and hepatocellular carcinoma (HCC), sponsored by Zelgen. Primary endpoints: Tolerability of Donafenib in Combination With KN046 at 21 days and Objective Response Rate up to 36 months. Started Jan 2021; status: terminated.
02
Drugs
donafeniberfonrilimab
03
Conditions
gastrointestinal tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04612712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612712.